Mizuho Maintains Buy on ResMed, Raises Price Target to $215
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Anthony Petrone has reaffirmed a Buy rating on ResMed (NYSE:RMD) and increased the price target from $195 to $215, indicating a positive outlook on the company's stock.
January 30, 2024 | 2:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Anthony Petrone maintains a Buy rating on ResMed and raises the price target to $215, suggesting a bullish stance on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential short-term rise in the stock price, as the market reacts to the positive endorsement.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100